Reason for request
Inclusion
Clinical Benefit
| Substantial |
Substantial actual benefit |
Clinical Added Value
| important |
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation. |
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
jfWju1x3PUMj8FtQ
